The California-headquartered biotech, which develops oral vaccines administered by tablet rather than injection, says a COVID-19 vaccine in this form would be ‘significantly’ easier and cheaper to store and distribute as it does not require a refrigerated cold chain like most injectable vaccines.
Having obtained the green light from the U.S. Food and Drug Administration (FDA) in its IND application, announced yesterday, enrolment for the Phase 1 clinical trial will begin this month with results anticipated in early 2021. It is the first oral tablet vaccine for COVID-19 to reach human clinical trials.
Vaxart’s COVID-19 vaccine is using the same platform technology as its more advanced influenza vaccine program, which released topline data from a Phase 2 challenge study earlier this year.
‘We made the strategic decision to pivot our focus to COVID-19’
Vaxart's focus is on developing tablet versions of currently marketed vaccines, as well as designing recombinant vaccines for new indications. All are based on its oral Vector-Adjuvant platform, VAAST.
Development programs include tablet vaccines for norovirus, seasonal influenza, and respiratory syncytial virus (RSV). The company has also a development program for a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immune-oncology indication.
At the start of this year, Vaxart started working on its coronavirus vaccine.
“In January, we felt a “call to duty” and made the strategic decision to pivot our focus to combatting COVID-19 using our proprietary vector platform,” Vaxart’s chief scientific officer, Sean Tucker Ph.D., told BioPharma-Reporter.
"enter" - Google News
September 15, 2020 at 05:30PM
https://ift.tt/2ZDMXtV
Vaxart's oral COVID-19 tablet vaccine to enter clinical trials - BioPharma-Reporter.com
"enter" - Google News
https://ift.tt/2TwxTMf
https://ift.tt/3d6LMHD
Bagikan Berita Ini
0 Response to "Vaxart's oral COVID-19 tablet vaccine to enter clinical trials - BioPharma-Reporter.com"
Post a Comment